Ground-breaking discovery opens door to new treatments for childhood brain cancer

10th July 2020

Scientists, part-funded by Worldwide Cancer Research, have uncovered a promising new treatment approach that in the future could improve survival for the most common type of childhood brain tumour - called medulloblastoma.

The research, carried out by a large collaborative group of cancer researchers from around the world, has shown that combining immunotherapy with a drug called TNF (tumour necrosis factor) could eradicate tumours that were otherwise unaffected by immunotherapy.

This ground-breaking research, although still in its early stages, has left scientists hopeful that clinical trials can be started as soon as possible to test the treatment combination in patients.

Although advances in surgery, radiotherapy and chemotherapy have improved survival for children with medulloblastoma, approximately 1 in 3 patients remain incurable. And those that survive often suffer long term side effects of treatments that impact the developing brain.

Targeted treatments, such as immunotherapy, can have less toxic side effects and could improve outcomes for these patients. However, not all patients benefit from immunotherapy due to genetic differences between tumours.

A better understanding of why this is the case will help researchers develop ways to make immunotherapy work for more people.

Hiding from the immune system

For some types of immunotherapy to work, the patient’s immune system must be able to detect cancer cells and eradicate them like it would against invading bacteria or viruses.

Some cancers can hide from the immune system because they are missing a molecule that scientists call MHC-1. This molecule normally sits on the surface of the cell and acts like a signal flare telling the immune system that something wrong with the cell and needs destroying.

With this molecule missing, cancer cells have an invisibility cloak that keeps them hidden from the immune system.

A ground-breaking discovery

In this new study, scientists discovered that the drug TNF could force MHC-1 back to the surface of these cancer cells, effectively stripping them of their invisibility cloak and making them open to attack from the immune system.

When they combined TNF with immunotherapy in mice with brain cancer, they discovered that brain tumours were melting away. Dr Robert Wechsler-Reya, who worked on the study, said in a statement:


Our findings suggest that some cancers may not respond to immunotherapy because the tumours don't have sufficient MHC-1 levels to trigger an effective immune response. Our hope is that in the near term, combining immunotherapy with TNF will increase the effectiveness of immunotherapy for children who are battling brain cancer.
Dr Robert Wechsler-Reya

Incredible discoveries like this would not happen without research – and research cannot happen without the support of people like you. If you’re feeling inspired, why not help us make the breakthroughs of the future by donating and starting new cancer cures today?


Further reading

Research News Breaking news photo

New drug could become one of the first targeted treatments for triple-negative breast cancer

Dr Najoua Lalaoui, a scientist at the Walter & Eliza Hall Institute of Medical Research in Australia, has been studying a new drug called birinapant. A drug which her research is showing could become one of the first targeted treatments for triple-negative breast cancer.

06 July 2020


Clinical trials for new cancer vaccine could start within three years

Scientists are ready to start clinical trials for a new cancer vaccine thanks to a recent research breakthrough. The team hope to begin clinical trials within the next three years.

29 July 2020

Breaking news photo

New cancer drug could help people with multiple myeloma

Scientists have discovered that a new drug could help overcome treatment resistance in advanced cases of multiple myeloma.

13 April 2020


Join our monthly newsletter

Keep up to date with all our latest news, events, groundbreaking research discoveries and much more!

You're now a Curestarter!

Our newsletter usually drops towards the end of each month

Thanks for subscribing